A new azole derivative of 1,4-benzothiazine increases the antifungal mechanisms of natural effector cells

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 9, 1999, Pages 2170-2175

  Pitzurra, Lucia ^a   Fringuelli, Renata ^a   Perito, Stefano ^a   Schiaffella, Fausto ^a   Barluzzi, Roberta ^a   Bistoni, Francesco ^a   Vecchiarelli, Anna ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

7 [1 [(4 CHLOROBENZYL)OXY] 2 (1H 1 IMIDAZOLYL)ETHYL] 4 METHYL 3,4 DIHYDRO 2H 1,4 BENZOTHIAZINE 3 ONE; ANTIFUNGAL AGENT; BENZOTHIAZINE DERIVATIVE; FLUCONAZOLE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDIASIS; DRUG EFFICACY; FEMALE; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PHAGOCYTOSIS; PRIORITY JOURNAL;

EID: 0032825192     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.9.2170     Document Type: Article

References (43)

1. Anaissie, E. J., N. C. Karyotakis, R. Hachem, M. C. Dignani, J. H. Rex, and V. Paetznick. 1994. Correlation between in vitro and in vivo activity of antifungal agents against Candida species. J. Infect. Dis. 170:384-389.
2. Barluzzi, R., R. Mazzolla, A. Brozzetti, M. Puliti, G. Mariucci, P. Mosci, F. Bistoni, and E. Blasi. 1997. A low virulent strain of C. albicans enhances brain anticryptococcal defenses: characterization of the local immune reaction by RT-PCR and histochemical analysis. J. Neuroimmunol. 79:37-48.
3. Beck-Sague, C., and W. R. Jarvis. 1993. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. J. Infect. Dis. 167:1247-1251.
4. Bistoni, F., A. Vecchiarelli, R. Mazzolla, P. Puccetti, P. Marconi, and E. Garaci. 1985. Immunoadjuvant activity of amphotericin B as displayed in mice infected with Candida albicans. Antimicrob. Agents Chemother. 27: 625-631.
5. Blasi, E., L. Pitzurra, M. Puliti, A. R. Chimienti, R. Mazzolla, R. Barluzzi, and F. Bistoni. 1995. Differential susceptibility of yeast and hyphal forms of Candida albicans to macrophage-derived nitrogen-containing compounds. Infect. Immun. 63:1806-1809.
6. Bodey, G. P. 1966. Fungal infections complicating acute leukemia. J. Chronic Dis. 19:667-687.
7. Casadevall, A., W. Cleare, M. Feldmesser, A. Glatman-Freedman, D. L. Goldman, T. R. Kozel, N. Lendvai, J. Mukherjee, L. A. Pirofski, J. Rivera, A. L. Rosas, M. D. Scharff, P. Valadon, K. Westin, and T. Zhong. 1998. Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies. Antimicrob. Agents Chemother. 42:1437-1446.
8. Cassone, A., P. Marconi, F. Bistoni, E. Mattia, G. Sbaraglia, E. Garaci, and E. Bonmassar. 1981. Immunoadjuvant effects of Candida albicans and its cell wall fractions in a mouse lymphoma model. Cancer Immunol. Immunother. 10:181-190.
9. Cenci, E., L. Romani, A. Mencacci, R. Spaccapelo, E. Schiaffella, P. Puccetti, and F. Bistoni. 1993. Interleukin-4 and interleukin-10 inhibit nitric oxide-dependent macrophage killing of Candida albicans. Eur. J. Immunol. 23: 1034-1038.
10. Decker, T., M.-L. Lohmann-Matthes, and M. Baccarini. 1986. Heterogeneous activity of immature and mature cells of the murine monocyte-macrophage lineage derived from different anatomical districts against yeast-phase Candida albicans. Infect. Immun. 54:477-486.
11. Fisher-Hoch, S. P., and L. Hutwagner. 1995. Opportunistic candidiasis: an epidemic of the 1980s. Clin. Infect. Dis. 21:897-904.
12. Fringuelli, R., F. Schiaffella, F. Bistoni, L. Pitzurra, and A. Vecchiarelli. 1998. Azole derivatives of 1,4-benzothiazine as antifungal agents. Bioorg. Med. Chem. 6:103-108.
13. Garcha, U. K., E. Brummer, and D. A. Stevens. 1995. Synergy of fluconazole with macrophages for antifungal activity against Candida albicans. Mycopathologia 132:123-128.
14. Georgopapadakou, N. H., and T. J. Walsh. 1996. Antifungal agents: chemotherapeutic targets and immunologic strategies. Antimicrob. Agents Chemother. 40:279-291.
15. Gujral, S., E. Brummer, and D. A. Stevens. 1966. Role of extended culture time on synergy of fluconazole and human monocyte-derived macrophages for killing Candida species. J. Infect. Dis. 174:888-889.
16. Hata, K., J. Kimura, H. Miki, T. Toyosawa, T. Nakamura, and K. Katsu. 1996. In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum. Antimicrob. Agents Chemother. 40:2237-2242.
17. Hitchcock, C. A., G. W. Pye, G. P. Oliver, and P. F. Troke. 1995. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: antifungal activity and selectivity in vitro, abstr. F72, p. 125. In Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
18. Komashian, S. V., A. K. Uwaydah, J. D. Sobel, and L. R. Crame. 1989. Fungemia caused by Candida species and Torulopsis glabrata in hospitalized patients: frequency, characteristics, and evaluation of factors influencing outcome. Rev. Infect. Dis. 11:379-390.
19. Louie, A., A. L. Baltch, M. A. Franke, R. P. Smith, and M. A. Gordon. 1994. Comparative capacity of four antifungal agents to stimulate murine macrophages to produce tumor necrosis factor alpha. An effect that is attenuated by pentoxifylline, liposomal vesicles, and dexamethasone. J. Antimicrob. Chemother. 34:975-987.
20. Louie, A., A. L. Baltch, and R. P. Smith. 1994. Tumor necrosis factor alpha has a protective role in a murine model of systemic candidiasis. Infect. Immun. 62:2761-2772.
21. Louie, A., A. L. Baltch, R. P. Smith, M. A. Franke, W. J. Ritz, J. K. Singh, and M. A. Gordon. 1995. Fluconazole and amphotericin B antifungal therapies do not negate the protective effect of endogenous tumor necrosis factor in a murine model of fatal disseminated candidiasis. J. Infect. Dis. 171:406-415.
22. Marodi, L., J. R. Forehand, and R. B. Johnston, Jr. 1991. Mechanisms of host defense against Candida species. II. Biochemical basis for the killing of Candida by mononuclear phagocytes. J. Immunol. 146:2790-2794.
23. Marodi, L., C. Tournay, R. Kaposzta, R. B. Johnston, Jr., and N. Moguilevsky. 1998. Augmentation of human macrophage candidacidal capacity by recombinant human myeloperoxidase and granulocyte-macrophage colony-stimulating factor. Infect. Immun. 66:2750-2754.
24. McElhaney-Feser, G. E., R. E. Raulli, and R. L. Cihlar. 1998. Synergy of nitric oxide and azoles against Candida species in vitro. Antimicrob. Agents Chemother. 42:2342-2346.
25. Mukherjee, J., M. Feldmesser, M. D. Scharf, and A. Casadevall. 1995. Monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan enhance fluconazole efficacy. Antimicrob. Agents Chemother. 39:1398-1405.
26. Natarajan, U., N. Randhawa, E. Brummer, and D. A. Stevens. 1998. Effect of granulocyte-macrophage colony-stimulating factor on candidacidal activity of neutrophils, monocytes or monocyte-derived macrophages and synergy with fluconazole. J. Med. Microbiol. 47:359-363.
27. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard. NCCLS document M27-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
28. Norman, G. R., and D. L. Streiner. 1986. Non-parametric statistics, p. 79-82. In PDQ statistics. B. C. Decker Inc., Toronto, Ontario, Canada.
29. Nosanchuk, J. D., W. Cleare, S. P. Franzot, and A. Casadevall. 1999. Amphotericin B and fluconazole affect cellular charge, macrophage phagocytosis, and cellular morphology of Cryptococcus neoformans at subinhibitory concentrations. Antimicrob. Agents Chemother. 43:233-239.
30. Perfect, J. R., D. L. Granger, and D. T. Durack. 1987. Effects of antifungal agents and gamma interferon on macrophage cytotoxicity for fungi and tumor cells. J. Infect. Dis. 156:316-323.
31. Rex, J. H., P. W. Nelson, V. L. Paetznick, M. Lozano-Chiu, A. Espinel-Ingroff, and E. J. Anaissie. 1998. Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis. Antimicrob. Agents Chemother. 42:129-134.
32. Rex, J. H., M. A. Pfaller, J. N. Galgiani, M. S. Bartlett, A. Espinel-Ingroff, M. A. Ghannoum, M. Lancaster, F. C. Odds, M. G. Rinaldi, T. J. Walsh, A. L. Barry, and Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. 1997. Development of interpretative breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin. Infect. Dis. 24:235-247.
33. Rubin, B. Y., S. L. Anderson, S. A. Sullivan, B. D. Williamson, E. A. Carswell, and L. J. Old. 1985. Purification and characterization of a human tumor necrosis factor from the LuKII cell line. Proc. Natl. Acad. Sci. USA 82:6637-6641.
34. Schroter, G. P. J., M. Hoelscher, C. W. Putman, K. A. Porter, and T. E. Starzl. 1977. Fungus infections after liver transplantation. Ann. Surg. 186: 115-122.
35. Sheehan, D. J., A. C. Hitchcock, and C. M. Sibley. 1999. Current and emerging azole antifungal agents. Clin. Microbiol. Rev. 12:40-79.
36. van Etten, E. W., N. E. van de Rhee, K. M. van Kampen, and I. A. Bakker-Woudenberg. 1991. Effects of amphotericin B and fluconazole on the extracellular and intracellular growth of Candida albicans. Antimicrob. Agents Chemother. 35:2275-2281.
37. van Uden, N., and H. Buckley. 1970. Candida Berkhout, p. 914. In J. Lodder (ed.), The yeasts: a taxonomic study. North-Holland Publishing Co., Amsterdam, The Netherlands.
38. Vazquez-Torres, A., and E. Balish. 1997. Macrophages in resistance to candidiasis. Microbiol. Mol. Biol. Rev. 61:170-192.
39. Vecchiarelli, A., M. Dottorini, C. Cociani, D. Pletrella, T. Todisco, and F. Bistoni. 1993. Mechanism of intracellular candidacidal activity mediated by calcium ionophore in human alveolar macrophages. Am. J. Respir. Cell Mol. Biol. 9:19-25.
40. Vecchiarelli, A., G. Verducci, S. Perito, P. Puccetti, P. Marconi, and F. Bistoni. 1986. Involvement of host macrophages in the immunoadjuvant activity of amphotericin B in a mouse fungal infection model. J. Antibiot. 39:846-855.
41. Vora, S., N. Purimetla, E. Brummer, and D. A. Stevens. 1998. Activity of voriconazole, a new triazole, combined with neutrophils or monocytes against Candida albicans: effect of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. Antimicrob. Agents Chemother. 42:907-910.
42. Wey, S. B., M. Mori, M. A. Pfaller, R. F. Woolson, and R. P. Wenzel. 1988. Hospital-acquired candidemia. The attributable mortality and excess length of stay. Arch. Intern. Med. 148:2642-2645.
43. White, T. C., K. A. Marr, and R. A. Bowden. 1998. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin. Microbiol. Rev. 11:382-402.